MILWAUKEE, Feb. 12, 2024 /PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY)  for possible breaches of fiduciary duty and other violations of law in its transaction with Gilead.

AdemiLogo (PRNewsfoto/Ademi LLP)

Click here to learn how to join the https://www.ademilaw.com/case/cymabay-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, CymaBay shareholders will receive only $32.50 per share transaction valuing the CymaBay at a total equity value of $4.3 billion. The transaction agreement unreasonably limits competing transactions for CymaBay by imposing a significant penalty if CymaBay accepts a competing bid. CymaBay insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of CymaBay's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own CymaBay common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/cymabay-therapeutics-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                    
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-cymabay-therapeutics-inc--has-obtained-a-fair-price-in-its-transaction-with-gilead-302059535.html

SOURCE Ademi LLP